HOME >> MEDICINE >> NEWS
Injectable drug, combined with counseling, shows promise in treating alcohol dependence

overing how best to provide treatment -- like adding a safe medication to counseling. A long-acting injectable, which eliminates the burden of daily pill taking, will open new doors for our patients and give hope to them and their families," adds Dr. Pettinati.

A total of 627 alcohol-dependent patients were randomly assigned to receive either an injection of long-acting naltrexone or a placebo injection; 624 ultimately received at least one injection. In addition to an injection, all participants received low-intensity counseling consisting of 12 sessions during the six-month study, in addition to study medication. Long-acting naltrexone was associated with a reduction in heavy drinking within the first month of treatment, and this response was maintained over the six-month treatment period. In addition, long-acting naltrexone was generally well tolerated and side effects were predominantly mild and decreased over time. (The three most common side effects reported were nausea, headache and fatigue.)

The study was one of the largest trials of a medication for alcohol dependence and was conducted at 24 sites nationwide, including public, private hospitals and Veterans Administration clinics and tertiary-care medical centers. Other study authors included researchers from the medical schools at the University of Connecticut, Yale University, and Harvard University, and from Alkermes Incorporated, a biotechnology company based in Cambridge, Mass., that manufactures the long-acting naltrexone formulation (Vivitrex) used in the study.


'"/>

Contact: Ed Federico
ed.federico@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
5-Apr-2005


Page: 1 2

Related medicine news :

1. Mistletoe is not an anti-cancer drug, say doctors
2. RAND study shows solitary drug, alcohol and cigarette use puts adolescents at higher risk
3. The Journal of Clinical Pharmacology looks at effects of smoking cessation drug, varenicline
4. Stubborn ulcerative colitis responds to arthritis drug, review finds
5. Brain power combined to form new $125M institute
6. New study demonstrates combined techniques to detect, monitor Alzheimers disease
7. TPV EU approval provides new HIV active drug to be combined with FUZEON
8. 1.7m to build worlds first SIMS instrument combined with infra-red spectroscopy
9. Antibody combined with cancer drug shows promise against breast tumors
10. Targeted cancer drug combined with low-dose chemotherapy shrinks tumors, slows ovarian cancer
11. Medication combined with behavior therapy works best for ADHD children, study finds

Post Your Comments:
(Date:10/20/2014)... Succeed is proud to announce that they ranked ... the Every Body Walk! campaign by Kaiser Permanente. ... encourages workers to be more active outside of the workplace. ... at the end of September, was a friendly competition between ... Participating companies gave their staff pedometers and each day, ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
(Date:10/19/2014)... 19, 2014 Dr. Babatunde Osotimehin, Executive ... news of a ceasefire agreement that is expected to ... girls who were kidnapped from the north-eastern Nigerian town ... captivity long enough, and it is high time they ... Dr. Osotimehin. , "We owe it to these girls ...
(Date:10/19/2014)... October 20, 2014 Recently, Fancyflyingfox.com, an ... occasion clothes, has announced its latest designs of 2014 ... all the new elegant outfits are offered with big ... an order before October 30 can enjoy this special ... great marketing strategies, it has become one of the ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
(Date:10/17/2014)... DUBLIN , October 17, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has ... Market Monitor : North American Automated ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The ... forecast, 2008-2018 analyzes the market of ...
(Date:10/17/2014)... 2014 Investor-Edge has initiated coverage ... ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ), and ... these five companies can be accessed at: http://investor-edge.com/register ... 16, 2014, ended on a mixed note as the ...
(Date:10/17/2014)... Wash. , Oct. 17, 2014  Talyst, a ... the 2014 LeadingAge Annual Meeting in Nashville, ... InSite System, the market leading solution for onsite, remote ... long term care facilities to safely and securely dispense ... time to first dose, helps ensure that the correct ...
Breaking Medicine Technology:Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2
Cached News: